Old drug, in a low dose, safe and effective in preventing progression of type 1 diabetes in children and young people

New research presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria (15–19 September) and published simultaneously in The Lancet shows that a much lower dose than previously thought of the old immunomodulatory drug anti-thymocyte globulin (ATG) is safe and effective in preventing progression of type 1 diabetes (T1D) in young people.

👉 Full Story